148 related articles for article (PubMed ID: 30578577)
1. The effect of rapid infusion of cisplatin on nephrotoxicity in patients with lung carcinoma.
Mense ES; Smit AAJ; Crul M; Franssen EJF
J Clin Pharm Ther; 2019 Apr; 44(2):249-257. PubMed ID: 30578577
[TBL] [Abstract][Full Text] [Related]
2. Difference in decline in renal function due to cisplatin after a short or long hydration scheme in non-small-cell lung cancer: A retrospective cohort study (HYCIS-XL).
Niggebrugge-Mentink KL; Beex-Oosterhuis MM; Ter Horst PGJ; van de Poll MEC; Dieleman HG; van Kesteren C
J Clin Pharm Ther; 2020 Oct; 45(5):1153-1158. PubMed ID: 32533904
[TBL] [Abstract][Full Text] [Related]
3. Safety of oral hydration after cisplatin infusion in an outpatient lung cancer unit.
Puisset F; Bigay-Game L; Paludetto MN; Martel A; Perriat S; Rabeau A; Canonge JM; Mazieres J
Support Care Cancer; 2019 May; 27(5):1679-1686. PubMed ID: 30120556
[TBL] [Abstract][Full Text] [Related]
4. Risk Factors Associated with Cisplatin-Induced Nephrotoxicity in Patients with Advanced Lung Cancer.
Miyoshi T; Misumi N; Hiraike M; Mihara Y; Nishino T; Tsuruta M; Kawamata Y; Hiraki Y; Kozono A; Ichiki M
Biol Pharm Bull; 2016; 39(12):2009-2014. PubMed ID: 27904042
[TBL] [Abstract][Full Text] [Related]
5. Impact of acute kidney injury defined by CTCAE v4.0 during first course of cisplatin-based chemotherapy on treatment outcomes in advanced urothelial cancer patients.
Ishitsuka R; Miyazaki J; Ichioka D; Inoue T; Kageyama S; Sugimoto M; Mitsuzuka K; Matsui Y; Shiraishi Y; Kinoshita H; Wakeda H; Nomoto T; Kikuchi E; Kawai K; Nishiyama H
Clin Exp Nephrol; 2017 Aug; 21(4):732-740. PubMed ID: 27565169
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel by 96-hour continuous infusion in combination with cisplatin: a phase I trial in patients with advanced lung cancer.
Georgiadis MS; Schuler BS; Brown JE; Kieffer LV; Steinberg SM; Wilson WH; Takimoto CH; Kelley MJ; Johnson BE
J Clin Oncol; 1997 Feb; 15(2):735-43. PubMed ID: 9053499
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Renal Outcomes after Cisplatin Treatment.
Latcha S; Jaimes EA; Patil S; Glezerman IG; Mehta S; Flombaum CD
Clin J Am Soc Nephrol; 2016 Jul; 11(7):1173-1179. PubMed ID: 27073199
[TBL] [Abstract][Full Text] [Related]
8. [Combination chemotherapy with Taxol and cisplatin for 57 patients with non-small cell lung cancer by intraartery and intravenous infusion].
Zhao Y; Wang SM; Zhang J
Ai Zheng; 2002 Dec; 21(12):1365-7. PubMed ID: 12520750
[TBL] [Abstract][Full Text] [Related]
9. Correlation of prechemotherapy urinary megalin ectodomain (A-megalin) levels with the development of cisplatin-induced nephrotoxicity: a prospective observational study.
Shoji S; Hosojima M; Kabasawa H; Kondo R; Miura S; Watanabe S; Aoki N; Kaseda R; Kuwahara S; Tanabe N; Hirayama Y; Narita I; Kikuchi T; Kagamu H; Saito A
BMC Cancer; 2019 Dec; 19(1):1170. PubMed ID: 31791266
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma.
Camidge DR; Blais N; Jonker DJ; Soulières D; Doebele RC; Ruiz-Garcia A; Thall A; Zhang K; Laurie SA; Chao RC; Chow LQ
Cancer Chemother Pharmacol; 2013 Feb; 71(2):307-19. PubMed ID: 23108697
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.
Hainsworth JD; Greco FA
Semin Oncol; 1995 Dec; 22(6 Suppl 15):45-9. PubMed ID: 8643970
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced non-small cell lung cancer.
Breathnach OS; Georgiadis MS; Schuler BS; Pizzella P; Llorens V; Kasturi V; Steinberg SM; O'Neil K; Takimoto CH; Johnson BE
Clin Cancer Res; 2000 Jul; 6(7):2670-6. PubMed ID: 10914708
[TBL] [Abstract][Full Text] [Related]
13. Understanding the Risk Factors and Long-Term Consequences of Cisplatin-Associated Acute Kidney Injury: An Observational Cohort Study.
Bhat ZY; Cadnapaphornchai P; Ginsburg K; Sivagnanam M; Chopra S; Treadway CK; Lin HS; Yoo G; Sukari A; Doshi MD
PLoS One; 2015; 10(11):e0142225. PubMed ID: 26556481
[TBL] [Abstract][Full Text] [Related]
14. Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma.
Tiseo M; Martelli O; Mancuso A; Sormani MP; Bruzzi P; Di Salvia R; De Marinis F; Ardizzoni A
Tumori; 2007; 93(2):138-44. PubMed ID: 17557559
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of cisplatin, 5-fluorouracil, and leucovorin augmented by vinorelbine (Navelbine) for advanced non-small cell lung cancer: rationale and study design.
Vokes EE; Drinkard LC; Samuels BL; Hoffman PC; Watson S; Bitran JD; Haraf DJ; Ferguson MF; Golomb HM
Semin Oncol; 1994 Oct; 21(5 Suppl 10):79-83; discussion 83-4. PubMed ID: 7973772
[TBL] [Abstract][Full Text] [Related]
16. Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors.
Sato K; Watanabe S; Ohtsubo A; Shoji S; Ishikawa D; Tanaka T; Nozaki K; Kondo R; Okajima M; Miura S; Tanaka J; Sakagami T; Koya T; Kagamu H; Yoshizawa H; Narita I
BMC Cancer; 2016 Mar; 16():222. PubMed ID: 26979596
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
Belli L; LeChevalier T; Gottfried M; Adams D; Ruffie P; LeCesne A; Tete L; Pellae-Cosset B
Semin Oncol; 1995 Dec; 22(6 Suppl 15):29-33. PubMed ID: 8643967
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of irinotecan and infusional cisplatin for advanced non-small-cell lung cancer.
Mori K; Ohnishi T; Yokoyama K; Tominaga K
Cancer Chemother Pharmacol; 1997; 39(4):327-32. PubMed ID: 9025773
[TBL] [Abstract][Full Text] [Related]
19. Concurrent paclitaxel/cisplatin with thoracic radiation in patients with stage IIIA/B non-small cell carcinoma of the lung.
Antonia SJ; Wagner H; Williams C; Alberts M; Hubbell D; Robinson L; Hilstro J; Ruckdeschel JC
Semin Oncol; 1995 Aug; 22(4 Suppl 9):34-7. PubMed ID: 7644926
[TBL] [Abstract][Full Text] [Related]
20. [Incidence, risk factors and prevention of cisplatin-induced nephrotoxicity in patients with lung cancer].
Losonczy G; Máthé C; Müller V; Szondy K; Moldvay J
Magy Onkol; 2010 Dec; 54(4):289-96. PubMed ID: 21163759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
